Search - tctmd.com

Displaying 1 - 20 of 306

Sort: Relevancy | Date

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Michael O'Riordan

December 12, 2025

News Daily News

Risk Calculators Miss Many Patients Who Present With First MI

Michael O'Riordan

November 21, 2025

News Daily News

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Yael L. Maxwell

October 23, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

L.A. McKeown

September 22, 2025

News Daily News

Evolocumab Gains Expanded Indication for Primary Prevention

Michael O'Riordan

August 26, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Advertisement

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Patients With Obesity Get Biggest Benefit from Evolocumab: FOURIER

Risk Calculators Miss Many Patients Who Present With First MI

Biomarkers Added to a Polygenic Risk Score Equals Better CAD Prediction

Evolocumab Wins for Primary Prevention in VESALIUS-CV

CVD Still the Leading Cause of Death and Disease Globally

Good LDL Control When PCSK9 Inhibitors Given In-Hospital After Interventions

Evolocumab Gains Expanded Indication for Primary Prevention

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content